Cover
Cover | Mar. 17, 2023 |
Document Information [Line Items] | |
Document Type | 8-K/A |
Document Period End Date | Mar. 17, 2023 |
Entity Registrant Name | CalciMedica, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39538 |
Entity Tax Identification Number | 45-2120079 |
Entity Address, Address Line One | 505 Coast Boulevard South |
Entity Address, Address Line Two | Suite 307 |
Entity Address, City or Town | La Jolla |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92037 |
City Area Code | 858 |
Local Phone Number | 952-5500 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | CALC |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Amendment Flag | true |
Amendment Description | This Amendment No. 2 on Form 8-K/A (this “Amendment No. 2”) amends the Form 8-K/A of CalciMedica, Inc. (the “Company”) filed on April 4, 2023 (the “Original Report”) with the Securities and Exchange Commission (the “SEC”) to restate each of (i) the Company’s financial statements as of and for the year ended December 31, 2022, as included in Exhibit 99.1 of the Original Report and (ii) the unaudited pro forma combined financial statements as of and for the year ended December 31, 2022, as included in Exhibit 99.2 of the Original Report (collectively, the “Financial Statements”). On May 12, 2023, the Company filed a Current Report on Form 8-K disclosing that the Financial Statements included in the Original Report should not be relied upon. Other than this Explanatory Note, the section entitled “Restatement Background” and the restated Financial Statements and Consent of Independent Registered Public Accounting Firm included under Item 9.01, this Amendment No. 2 does not amend, update or change any other items or disclosures in the Original Report and does not purport to reflect any information or events subsequent to the filing thereof. As such, this Amendment No. 2 speaks only as of the date the Original Report was filed, and the Company has not undertaken herein to amend, supplement or update any information contained in the Original Report to give effect to any subsequent events. Accordingly, this Amendment No. 2 should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Report, including any amendment to those filings. The restatement is more fully described in Note 2 of the notes to the financial statements included herein. |
Entity Central Index Key | 0001534133 |